Completed PHASE3 INTERVENTIONAL NCT00252291

Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics

A Phase III Multicenter Study to Demonstrate the Sensitivity and Specificity of Aridol (Mannitol) Challenge to Predict Bronchial Hyperresponsiveness as Manifested by a Positive Exercise Challenge in Subjects Presenting With Signs and Symptoms Suggestive of Asthma But Without a Definitive Diagnosis

Sponsor: Syntara

Conditions Asthma

Interventions Aridol Exercise challenge Methacholine

Updated 6 times since 2017 Last updated: Nov 29, 2009 Started: Nov 30, 2005 Completion: Sep 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Asthma and is currently completed. Syntara leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Syntara

Data source: Syntara

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Denver, United States